Mirum Pharmaceuticals
MIRM
99 hedge funds and large institutions have $569M invested in Mirum Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
44% more capital invested
Capital invested by funds: $396M → $569M (+$173M)
41% more call options, than puts
Call options by funds: $904K | Put options by funds: $641K
15% more funds holding
Funds holding: 86 → 99 (+13)
3.52% more ownership
Funds ownership: 80.98% → 84.5% (+3.5%)
17% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 29
Top Buyers
Top Sellers
MIRM Hedge Fund Activity: Q1 2022 in Review
99 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q1 2022, worth a combined $569M — up 44% from $396M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MIRM positions and 15 closed out — a net gain of 13 holders — while 24 added to existing stakes and 29 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $19.9M. The largest seller was Frazier Management, exiting entirely with an estimated $56.9M sold.
- 99 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q1 2022, up from 86 in Q4 2021.
- Funds reported $569M of Mirum Pharmaceuticals stock for Q1 2022, up 44% quarter-over-quarter.
- 28 funds opened new Mirum Pharmaceuticals positions in Q1 2022 and 15 closed out, a net change of +13 holders.
- The largest Mirum Pharmaceuticals buyer in Q1 2022 was Polar Capital Holdings, an estimated $19.9M added.
- The largest Mirum Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $56.9M sold.
Based on aggregated 13F filings for Q1 2022.